Highlights from the 2018 American Heart Association Scientific Sessions in Chicago, Illinois
- 19 Downloads
After another exciting conference, this article highlights some of the many studies presented. We encourage readers to explore the broader content of the AHA presentations for other interesting studies.
Eicosapentaenoic acid (EPA) preparation demonstrates cardiovascular outcomes benefit
In patients treated with standard of care therapies (e.g. statins), risk for atherothrombotic events remains high. The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) studied the efficacy and safety of a purified and stable EPA preparation for the reduction of cardiovascular (CV) events in high risk patients with controlled low-density lipoprotein cholesterol (LDL-C) but elevated triglycerdies . Key eligibility criteria were: (1) age ≥ 45 years with established CV disease or age ≥ 50 years with diabetes mellitus and at least one additional risk factor; (2) fasting triglyceride level of 150–499 mg/dL; and (3) fasting LDL-C of 41–100 mg/dL on a stable dose of...
KeywordsConference Highlights Trials Review
- 4.Zelniker TA, Wiviott SD, Raz I et al (2018) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. https://doi.org/10.1016/S0140-6736(18)32590-X PubMedGoogle Scholar